The global ocular drug delivery technology market is projected to reach US$ 30.2 billion by 2034, driven by the increasing prevalence of eye conditions like glaucoma, diabetic retinopathy, and age-related macular degeneration. Advancements in drug delivery systems, including sustained-release formulations, nanoparticles, and biodegradable implants, are fueling market growth. The demand for non-invasive and comfortable treatment options is driving the adoption of technologies like punctal plugs, inserts, and contact lenses.